HBMN — HBM Healthcare Investments AG Share Price
Last trade - 00:00- CH₣1.21bn
- CH₣1.30bn
- CH₣23.19m
- 70
- 81
- 73
- 91
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.68 | ||
| PEG Ratio (f) | 0.22 | ||
| EPS Growth (f) | 111.19% | ||
| Dividend Yield (f) | 4.7% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.71 | ||
| Price to Tang. Book | 0.71 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.91 | ||
| EV to EBITDA | 5.92 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.45% | ||
| Return on Equity | 13.69% | ||
| Operating Margin | 91.04% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 235.06 | 917.13 | -37.57 | -117.56 | 23.19 | 76.9 | 132.3 | -38.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -12.61 | +313.95 | n/a | n/a | n/a | n/a | +111.19 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.
Directors
- Hans Hasler CHM (65)
- Andreas Wicki CEO (62)
- Heinz Riesenhuber VCH (85)
- Erwin Troxler CFO (51)
- Benedikt Suter SEC (57)
- Mario Giuliani DRC (49)
- Eduard Holdener DRC (76)
- Robert Ingram DRC
- Rudolf Lanz DRC (71)
- Stella Xu DRC (50)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 9th, 2001
- Public Since
- February 14th, 2008
- No. of Shareholders
- 3,905
- Sector
- Investment Banking & Investment Services
- Industry
- Financials
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 6,771,780
- Address
- Bundesplatz 1, ZUG, 6300
- Web
- https://www.hbmhealthcare.com/
- Phone
- +41 417107577
- Auditors
- Ernst & Young AG
Latest News for HBMN
Upcoming Events for HBMN
Q4 2025 HBM Healthcare Investments AG Earnings Release
HBM Healthcare Investments AG Annual Shareholders Meeting
Q1 2026 HBM Healthcare Investments AG Earnings Release
Similar to HBMN
Airesis SA
SIX Swiss Exchange
Alpine Select AG
SIX Swiss Exchange
Bellevue AG
SIX Swiss Exchange
Castle Private Equity AG
SIX Swiss Exchange
Compagnie financiere Tradition SA
SIX Swiss Exchange
FAQ
As of Today at 21:02 UTC, shares in HBM Healthcare Investments AG are trading at CH₣178.60. This share price information is delayed by 15 minutes.
Shares in HBM Healthcare Investments AG last closed at CH₣178.60 and the price had moved by -3.98% over the past 365 days. In terms of relative price strength the HBM Healthcare Investments AG share price has underperformed the FTSE Global All Cap Index by -5.67% over the past year.
The overall consensus recommendation for HBM Healthcare Investments AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe HBM Healthcare Investments AG dividend yield is 4.2% based on the trailing twelve month period.
Last year, HBM Healthcare Investments AG paid a total dividend of CH₣7.50, and it currently has a trailing dividend yield of 4.2%. We do not have any data on when HBM Healthcare Investments AG is to next pay dividends.
We do not have data on when HBM Healthcare Investments AG is to next pay dividends. The historic dividend yield on HBM Healthcare Investments AG shares is currently 4.2%.
To buy shares in HBM Healthcare Investments AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣178.60, shares in HBM Healthcare Investments AG had a market capitalisation of CH₣1.21bn.
Here are the trading details for HBM Healthcare Investments AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: HBMN
Based on an overall assessment of its quality, value and momentum HBM Healthcare Investments AG is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in HBM Healthcare Investments AG is CH₣233.50. That is 30.74% above the last closing price of CH₣178.60.
Analysts covering HBM Healthcare Investments AG currently have a consensus Earnings Per Share (EPS) forecast of CH₣7.24 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HBM Healthcare Investments AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -1.5%.
As of the last closing price of CH₣178.60, shares in HBM Healthcare Investments AG were trading -3.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HBM Healthcare Investments AG PE ratio based on its reported earnings over the past 12 months is 11.68. The shares last closed at CH₣178.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
HBM Healthcare Investments AG's management team is headed by:
- Hans Hasler - CHM
- Andreas Wicki - CEO
- Heinz Riesenhuber - VCH
- Erwin Troxler - CFO
- Benedikt Suter - SEC
- Mario Giuliani - DRC
- Eduard Holdener - DRC
- Robert Ingram - DRC
- Rudolf Lanz - DRC
- Stella Xu - DRC